The Trader Harbor
  • Business
  • Politics
  • World News
  • Stocks
  • Business
  • Politics
  • World News
  • Stocks

The Trader Harbor

Stocks

Core PCE Data Has Powell Pleased – May Set Tone For Q2

by admin March 30, 2024
March 30, 2024
Core PCE Data Has Powell Pleased – May Set Tone For Q2

The Fed’s preferred gauge of inflation was released today and, according to Fed chief Jerome Powell, “it was good,” as there were no ugly surprises. This news could boost the markets, as sticky inflation data has had investors on edge amid interest rates that have remained relatively high. The stock and bond markets were of course closed today, however, so we won’t see a response from traders until next week.

Overall, we’re heading into next week on good terms, with the Dow, Nasdaq and the S&P 500 at new highs with small-cap stocks in an uptrend after posting an impressive 2.5%. In other positive news, we’re continuing to see a broadening out of participation well beyond the Magnificent Seven stocks which dominated last year’s top performance lists.

Daily Chart of S&P 500 Index

With so much bullish behavior, it may be difficult to determine where to focus your efforts so that you can outperform these strong markets. From my work, honing in on companies that have strong growth outlooks will always pay off, particularly during a bull market phase such as now.

Many of these faster-growing companies — particularly in Technology — have seen impressive returns year-to-date already, with consolidation phases needed before another leg up. Instead, I’m looking for stocks in areas such as Healthcare, which have entered a new uptrend after trending sideways over the past 3 weeks. While normally viewed as a defensive area of the markets, there’s plenty of fast-growing companies amid the development of new drugs and medical products.

Daily Chart of Healthcare Sector (XLV)

A prime example is Eli Lilly (LLY) which was added to my MEM Edge Report’s suggested holdings list in early January. In addition to the company’s popular weight loss drug Zepbound, which was approved late last year, The company is on track to see their Alzheimer’s drug approved next quarter.

LLY has been trending upward in a tight trading range in anticipation of this FDA approval, and this recent period of consolidation has allowed the stock to recover from an overbought condition during February. A close above its recent high of $800, coupled with a bullish MACD crossover, would put the stock into a strong buy zone.

Daily Chart of Eli Lilly (LLY)

Other newer areas are also beginning to emerge, and if you’d like to be alerted to new buy ideas in these areas, use this link here to trial my twice weekly MEM Edge report. You’ll also receive in-depth information regarding broader market conditions as well as sector rotation that’s taking place and why. I hope you’ll take advantage of this offer!

Warmly,

Mary Ellen McGonagle

MEM Investment Research

0
FacebookTwitterGoogle +Pinterest
previous post
Biden campaign reaches out to Nikki Haley voters in new ad: ‘Donald Trump doesn’t want your vote’
next post
The Fourth Bitcoin Halving Is Upon Us: Is Now the Time to Go Long?

Related Posts

Rates Look Set to Rise as TLT Resumes...

March 18, 2024

DP Trading Room: PMO Sort on Earnings Darlings

July 16, 2024

Big Tech Earnings, Fed Meeting, Jobs Report: Will...

July 31, 2024

S&P 500 Still Bullish: This Is What You...

June 11, 2024

Surge in TSLA and Strong AMZN Not Enough

May 25, 2024

Are the Magnificent 7 Still the Kings of...

November 16, 2024

KRE’s Impending Plunge: What This Emerging Crisis Means

March 28, 2024

What Does This Mean for the S&P 500...

August 21, 2024

Is This a Market Bubble – or Investor...

June 27, 2024

New Highs Coming or Will We Collapse? What...

July 27, 2024

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • Apple reveals complex system of App Store fees to avoid E.U. fine of 500 million euros

      June 30, 2025
    • Breakdown of NVDA’s Stock Price and S&P 500: Actionable Technical Insights

      June 30, 2025
    • Thom Tillis announces retirement from Senate after clash with Trump

      June 30, 2025
    • SCOOP: House Republican eyes bid for Thom Tillis Senate seat after Trump attack

      June 30, 2025
    • Dem delay tactic ends, debate begins on Trump’s ‘big, beautiful bill’

      June 30, 2025
    • GOP, Dem senators remain divided over Medicaid after Trump’s ‘big, beautiful bill’ vote

      June 30, 2025

    Categories

    • Business (1,272)
    • Politics (3,873)
    • Stocks (1,477)
    • Uncategorized (45)
    • World News (1,265)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: TheTraderHarbor, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 thetraderharbor.com | All Rights Reserved